Analysts’ Opinions Are Mixed on These Healthcare Stocks: Wave Life Sciences (WVE) and Bausch Health Companies (BHC)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Wave Life Sciences (WVE – Research Report) and Bausch Health Companies (BHC – Research Report).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wave Life Sciences (WVE)
Clear Street analyst William Maughan reiterated a Buy rating on Wave Life Sciences today and set a price target of $22.00. The company’s shares closed last Wednesday at $8.26.
According to TipRanks.com, Maughan is a 4-star analyst with an average return of
Wave Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $20.92, implying a 177.1% upside from current levels. In a report issued on October 16, Wedbush also maintained a Buy rating on the stock with a $18.00 price target.
See today’s best-performing stocks on TipRanks >>
Bausch Health Companies (BHC)
Truist Financial analyst Les Sulewski maintained a Hold rating on Bausch Health Companies today. The company’s shares closed last Wednesday at $5.90.
According to TipRanks.com, Sulewski is a 3-star analyst with an average return of
Currently, the analyst consensus on Bausch Health Companies is a Hold with an average price target of $8.33, implying a 34.6% upside from current levels. In a report issued on October 22, RBC Capital also maintained a Hold rating on the stock with a $10.00 price target.
Read More on WVE:
Disclaimer & DisclosureReport an Issue
- Wave Life Sciences: Strategic Potential and Promising Developments Highlighted by Buy Rating
- Wave Life Sciences Reports Positive INLIGHT Trial Results
- Wave Life ‘at cusp of new era’ in healthy weight loss, says Truist
- Wave Life Sciences jumps after presenting new WVE-007 data
- iBio price target raised to $6 from $5 at Oppenheimer
